CMPX: Recover Your Losses with Johnson Fistel’s Help!

Company Overview & Recent Developments

Compass Therapeutics, Inc. (NASDAQ: CMPX) is a clinical-stage biopharmaceutical company focused on oncology, developing proprietary antibody-based therapeutics for cancer (investors.compasstherapeutics.com). Its lead candidate, tovecimig (CTX-009) – a bispecific antibody targeting DLL4 and VEGF-A – was tested in a Phase 2/3 trial (COMPANION-002) for advanced biliary tract cancer. In late April 2026, Compass disclosed that tovecimig failed to improve the key overall survival (OS) endpoint in this study (www.globenewswire.com). Despite meeting the primary endpoint (tumor response rate) and showing a progression-free survival (PFS) benefit, the OS outcome was actually worse in the treatment arm (median 8.9 months vs 9.4 months for control) and not statistically significant (www.fiercebiotech.com) (www.fiercebiotech.com). The company attributed this miss to high crossover – over half of control patients later received tovecimig – which confounded the OS analysis (www.fiercebiotech.com). Following these results, CMPX’s stock price plunged nearly 60%, dropping from about $5 to ~$2 per share as investors reacted to the disappointing news (hg04.chromareport.com) (www.rttnews.com). In the aftermath, shareholder-rights law firm Johnson Fistel announced an investigation into whether Compass’s executives violated securities laws or misled investors, inviting shareholders who suffered losses to seek more information on recovering their losses (www.globenewswire.com) (www.globenewswire.com). This backdrop has raised the stakes for Compass, as it navigates the fallout from the trial and attempts to chart a path forward for tovecimig and its pipeline.

Dividend Policy & History

CMPX does not pay dividends and has no history of ever doing so. As a development-stage biotech, the company retains all capital to fund research rather than return cash to shareholders. In fact, Compass explicitly states that it has never declared or paid cash dividends on its stock and does not intend to for the foreseeable future (www.sec.gov). This means the stock’s dividend yield is 0%, and investors’ potential gains rely entirely on share price appreciation rather than income. Such a policy is typical for clinical biotechs, as any future profits are uncertain and are preferably reinvested into advancing drug candidates instead of being paid out. Investors seeking yield or regular income would need to look elsewhere, as Compass’s value proposition is purely growth and pipeline-driven (www.sec.gov) (www.sec.gov).

(AFFO/FFO metrics are not applicable here – those are used for real estate or cash-flowing businesses. Compass, as a pre-revenue biotech, has no funds-from-operations to report and currently generates negative cash flow.)

Leverage and Debt Maturities

Compass Therapeutics maintains a conservative balance sheet with virtually no debt. The company has financed its operations primarily through equity issuances and collaborations, avoiding long-term borrowings. As of December 31, 2025, Compass had $209 million in cash and marketable securities on hand (investors.compasstherapeutics.com). Total liabilities at year-end 2025 were only about $22.8 million, consisting mostly of accounts payable and lease obligations – there were no bank loans, bonds, or other interest-bearing debt outstanding (www.sec.gov) (www.sec.gov). In 2025, Compass bolstered its cash position by raising net proceeds of ~$129 million in a public stock offering, which more than offset its operating cash burn for the year (investors.compasstherapeutics.com). With this war chest, management estimates it has sufficient liquidity to fund operations into 2028 before needing additional capital (investors.compasstherapeutics.com). The lack of debt means no looming maturities or interest payments that could pressure the company in the near term. This low leverage provides financial flexibility and reduces default risk – a positive for shareholders, especially given the volatile nature of biotech development. Essentially, CMPX’s capital structure is equity-heavy, and its runway of cash should cover several years of R&D spending barring any major changes in plan.

Cash Flow and Coverage

As a clinical-stage biotech, Compass generates no meaningful operating cash flows yet – it is spending cash, not making it. In 2025, the company reported a net loss of $66.5 million (www.sec.gov), reflecting substantial R&D and administrative costs with zero product revenue (the only revenue was a small one-time licensing fee in 2024) (www.sec.gov). Traditional coverage ratios (like interest coverage or dividend coverage) are therefore not meaningful for CMPX, since it has no debt interest to service and pays no dividends. In fact, Compass earned more in interest income from its cash investments ($6.3 million in 2025) than it paid in interest expense (which was nil) (www.sec.gov). The critical “coverage” metric for a company like this is its cash runway – how long its cash can cover its operating burn. On that front, Compass appears to be in a reasonable position: it used about $49 million of cash for operations in 2025, and with $209 million in coffers, it projects being able to fund its activities for roughly 3+ years without needing new financing (investors.compasstherapeutics.com). This implies that even without any incoming revenue, the company can cover its R&D and overhead into 2028 using existing cash. However, investors should monitor the cash burn rate going forward – if development efforts accelerate (e.g. additional trials or an expanded pipeline) or if unexpected costs arise, that runway could shorten. In summary, Compass’s current cash comfortably covers its near-term needs, but until the company achieves positive cash flow (via a product approval or partnerships), it remains reliant on finite reserves.

Valuation

After the recent stock collapse, CMPX’s market valuation has been sharply reduced. At around $2 per share, the company’s market capitalization is roughly $350–360 million (given ~178 million shares outstanding) (www.rttnews.com). Notably, a substantial portion of this market cap is backed by cash on hand – with $209 million in cash and securities at year-end, Compass’s enterprise value (EV) (market cap minus net cash) is on the order of only ~$140–150 million. By traditional metrics, the stock is trading at about 1.8× book value (shareholders’ equity was ~$197 million as of Dec 2025) (www.sec.gov). Earnings-based multiples are not applicable, since Compass has no earnings (trailing twelve-month EPS is deeply negative). Instead, investors are valuing the company on pipeline potential and cash assets. The steep drop in price suggests the market is deeply discounting the probability of near-term commercialization for tovecimig in light of the mixed trial results (ng.investing.com). Essentially, at a $140M EV, the market is saying that beyond the cash, the company’s pipeline (including tovecimig’s prospects and other drug candidates) is only modestly valued – reflecting high uncertainty.

It’s worth noting that prior to the OS miss, CMPX’s valuation had run-up significantly on optimism about tovecimig. (For example, the stock traded above $5, implying nearly a $900M market cap before the data release.) Now, with the likelihood of an easy FDA approval in doubt, the valuation has reset. Some analysts still see underlying value: William Blair, for instance, noted that the totality of the data does show a clinical benefit (notably the PFS improvement), even if approval is not guaranteed (ng.investing.com). The company itself is continuing to pursue approval plans, suggesting management believes the addressable market (biliary tract cancers with no approved 2nd-line therapy) could justify regulatory flexibility (www.fiercebiotech.com). Thus, current valuation can be viewed as a sum of: the cash reserve (which limits downside) plus a heavily risk-adjusted estimate of pipeline upside. If tovecimig somehow secures approval or a partnership, or if another pipeline asset shows breakthrough results, the stock could rebound from these lows. Conversely, if regulatory or clinical setbacks continue, CMPX’s valuation could erode toward just its cash value. For now, the market’s pricing implies skepticism, pricing Compass more like an early-stage biotech platform than a near-commercial company.

Key Risks

Investing in Compass Therapeutics carries significant risks, consistent with its stage and recent events. Some of the major risk factors include:

– Regulatory/Approval Risk: The fate of tovecimig at the FDA is uncertain. The Phase 2/3 trial’s failure to hit the OS endpoint raises serious questions about approvability of the drug on the data available (ng.investing.com). While the PFS benefit is notable, regulators may require an additional confirmatory trial to demonstrate an overall survival advantage (or at least rule out harm). Compass has no approved products and explicitly warns that it may not generate product revenues for many years, if ever, unless its development efforts succeed (www.sec.gov). If the FDA refuses to accept a Biologics License Application (BLA) or demands more data, tovecimig’s development could be delayed or derailed. Given that Compass’s ability to eventually earn revenue hinges heavily on drug approvals (www.sec.gov) (www.sec.gov), a regulatory setback here would be extremely detrimental.

– Financial & Funding Risk: Ongoing losses and future funding needs present a risk. Compass is not generating revenue and incurs substantial R&D and overhead costs (it lost $66M in 2025) – its operations are sustained by its cash reserves (www.sec.gov). The company believes it has cash into 2028, but that assumes a certain pace of spending; any acceleration (e.g. new trials, faster pipeline expansion) or unexpected costs could shorten the runway. If tovecimig’s approval is delayed or a new Phase 3 trial is required, Compass might burn cash faster than anticipated and need to raise capital sooner. Accessing additional financing could be challenging if the stock remains depressed. An equity raise at current low prices would severely dilute shareholders, while debt financing (if attempted) could be costly and is often restrictive for a company with no revenue. In short, Compass’s viability long-term requires either a successful drug launch or continued external funding, and neither is assured. The company acknowledges that even if development goes well, it is uncertain when – if ever – substantial product sales will materialize (www.sec.gov).

– Pipeline Concentration Risk: Compass is heavily dependent on a single lead program. Tovecimig is the furthest advanced asset; its outcome will largely determine Compass’s fate in the near term. If it fails to reach the market, Compass will be left relying on much earlier-stage candidates (such as CTX-8371, CTX-471, CTX-10726) which will take years of development and face their own technical hurdles. The company itself notes that its ability to generate revenue “depends heavily on the successful development and eventual commercialization” of its current product candidates (www.sec.gov). This all-or-nothing profile means high clinical risk – a single trial failure (as just experienced) can wipe out a large portion of the company’s value and prospects (hg04.chromareport.com). While the broader pipeline provides some diversification, until those programs reach at least proof-of-concept, Compass is effectively a one-product story, amplifying the impact of any news (good or bad) about tovecimig.

– Legal and Reputation Risk: The fallout from the trial result has attracted legal scrutiny. Johnson Fistel’s investigation into potential wrongdoing by Compass’s management is a red flag (www.globenewswire.com). Although such shareholder lawsuits are common after biotech stock crashes — and no findings have been made yet — the allegations can be a distraction and, in a worst case, could lead to costly litigation or settlements. If evidence emerges that executives overstated the drug’s prospects or omitted material information, it could damage the company’s reputation and investor trust. Already, the investigation suggests some investors feel misled or dissatisfied with management’s communications (www.globenewswire.com). This situation may also put pressure on the company to improve transparency and could affect its relationship with regulators or partners. In sum, legal actions add another layer of risk for shareholders, on top of the scientific and financial uncertainties.

– Competition and Market Risk: Compass operates in a highly competitive biotech landscape. Larger pharmaceutical companies and other biotechs are pursuing immunotherapy and angiogenesis-targeting treatments as well, some with far greater resources. For example, major players are developing their own bispecific antibodies and combination regimens in oncology, and any breakthroughs by competitors could diminish tovecimig’s relevance. Compass acknowledges it faces competition from many pharma and biotech companies, including those with more experience and funding (www.sec.gov). Additionally, if an existing drug (or a new entrant) addresses biliary tract cancer in second-line, the market opportunity for tovecimig could shrink. Competition also extends to pipeline assets: recruiting patients in trials, attracting talent, and securing partnerships are all harder when competing against bigger companies. There is also market risk in the sense that investor sentiment towards small biotech can swing dramatically (risk-off periods can make funding scarce and valuations low). This volatility, combined with intense external competition, poses a continuous risk to Compass’s objectives (hg04.chromareport.com) (www.sec.gov).

Red Flags and Concern Areas

Beyond the general risks above, a few red flags have emerged in the CMPX story that warrant investor attention:

– Shareholder Investigation: The involvement of Johnson Fistel is a clear red flag. The firm’s investigation into Compass’s management suggests that there may be concerns about whether the company fully and fairly disclosed information or whether executives over-promised to investors (www.globenewswire.com). While this is still just an inquiry, the very fact it’s happening underscores a credibility issue. It indicates that the stock’s implosion has led to allegations (or at least suspicions) that investors were misled, which could point to aggressive or overly optimistic communications by management prior to the data release.

– Overly Optimistic Guidance: Management’s tone leading up to the trial readout might raise eyebrows. In early March 2026, Compass’s CEO referred to the upcoming PFS/OS data as potentially “transformational” for the company (investors.compasstherapeutics.com). This bullish statement, coming just weeks before the OS outcome turned out negative, set high expectations. Investors who took that optimism at face value were caught off guard by the poor OS result. The lack of any cautionary language about the risk of crossover effects in that statement could be seen as misguided optimism. In hindsight, this gap between promise and outcome may erode management’s credibility. It’s a warning sign when executives paint a rosy picture that isn’t borne out by the data, even if their excitement was in good faith.

– Trial Design Issues: The COMPANION-002 trial design itself can be viewed as a red flag in retrospect. By allowing more than half of control-arm patients to crossover to the treatment, the study almost guaranteed that measuring a clean overall survival benefit would be problematic. Indeed, the OS endpoint became “uninterpretable” due to this crossover (www.fiercebiotech.com). One could argue that the company should have anticipated this issue – crossover was intended to be patient-friendly, but it compromised the statistical outcome. If management did recognize this, investors might question whether it was communicated clearly that OS might be hard to prove. The situation creates a perception that there was a strategic misstep: either in trial planning (not mitigating the crossover impact) or in investor communication (not tempering expectations about OS). This doesn’t imply any malice, but it is a red flag on execution that has now cost shareholders dearly.

– Capital Raise Timing: While not overtly improper, it’s worth noting Compass raised a large amount of equity capital in 2025 after announcing positive interim results (ORR data) in early 2025. The $129 million financing bolstered the balance sheet (investors.compasstherapeutics.com), but from a shareholder perspective, the timing (following upbeat data) and the subsequent collapse of the stock may feel like a “bait and switch.” Essentially, the company sold stock to new investors at much higher prices on the back of partial good news, only for full data to reveal problems. Again, this isn’t unusual for biotech (companies routinely raise funds when their stock pops), and it was prudent for Compass to secure cash. However, for those who bought into that offering or around those highs, it’s a sore point. This sequence might be flagged by lawyers or investors as a sign that management took advantage of a high valuation window, leaving new shareholders holding the bag when the bad news hit. It underscores the importance of skepticism – even when interim news is positive – and careful due diligence on whether further risks remain (such as OS in this case).

In summary, the presence of a legal probe, the disparity between management’s optimistic messaging and outcomes, and some trial execution choices all serve as cautionary signs. These red flags suggest investors should scrutinize Compass’s communications and decisions closely going forward. Transparency and realistic guidance will be crucial to rebuilding confidence.

Open Questions and What to Watch

Looking ahead, there are several open questions and unresolved issues surrounding Compass Therapeutics. How these are answered will determine whether investors can ultimately recover losses or if further challenges lie ahead:

– Will tovecimig find a path to approval? The top question is whether the FDA will accept the PFS benefit (and ORR data) as sufficient for some form of approval or accelerated approval, despite the lack of OS improvement. Compass has stated plans to meet with the FDA in mid-2026 for a pre-BLA meeting (ng.investing.com). The outcome of that meeting is crucial. Will regulators green-light a BLA filing based on the data, perhaps requiring a post-market study, or will they insist on a new randomized trial to properly assess survival? Investors should watch for updates on FDA feedback. Any indication of an accelerated approval route (using PFS as a surrogate endpoint in this high-unmet-need population) would be a positive surprise. Conversely, if the FDA guides that a confirmatory Phase 3 trial is needed before approval, it would mean a multi-year delay and significant additional cost. In short, the regulatory verdict on tovecimig remains an open question, and it will heavily influence Compass’s fate.

– How will Compass strategize if the FDA outcome is negative or uncertain? Depending on what the FDA says, Compass’s Plan B (or Plan C) will be important. If the agency is not receptive to approving tovecimig now, will Compass proceed with another clinical trial to address the OS issue (perhaps restricting crossover or focusing on a subpopulation)? Does the company have the resources and willingness to continue development on its own in that scenario, or would it pivot to finding a partner or buyer for the asset? These questions are unanswered. The company’s continued assertion that it sees a path forward suggests it is not giving up (www.fiercebiotech.com), but investors will want clarity on what “forward” looks like: an outright approval filing, an accelerated approval with conditions, or additional studies. Until these plans crystallize, uncertainty will hang over the stock.

– Can the rest of the pipeline create value? Tovecimig’s drama aside, Compass does have other candidates in development – but they are in earlier stages. For example, CTX-8371 (a novel PD-1 x PD-L1 bispecific) showed encouraging signs in Phase 1, with “three robust responses” observed in heavily pre-treated patients (investors.compasstherapeutics.com). CTX-471 (a 4-1BB agonist antibody) is expected to enter Phase 2 trials in mid-2026 (investors.compasstherapeutics.com), and CTX-10726 (a PD-1 x VEGF-A bispecific) just entered the clinic. These programs could generate important data in late 2026 and 2027. Open questions: Will any of these mechanisms deliver strong efficacy signals that reignite investor enthusiasm? Can Compass advance them far enough on its own to attract a partnership or acquisition? Success from the pipeline could diversify the company’s bets beyond tovecimig, but it’s too early to tell if any will be a winner. Investors should watch for early trial readouts or collaborations on these assets, as they could provide upside (or, if negative, add downside). Right now, the pipeline’s potential is largely theoretical – it’s an important part of the story, but proof of concept is needed to assign it real value.

– How will the legal investigation and shareholder sentiment play out? Another open question is the outcome (or progression) of the Johnson Fistel investigation and any similar actions. Often multiple law firms jump in after a big stock drop. Will this culminate in a class-action lawsuit against Compass for securities fraud? If so, how might management respond – will they fight it, settle quietly, or could it prompt changes (in leadership or disclosure practices)? While such legal matters can take a long time to resolve, any material developments (a lawsuit filing, a court decision) would be noteworthy for investors. Additionally, shareholder sentiment in general is a question: After a 60% loss, will the investor base turn over? Will we see activist investors emerge, or insiders buying on the dip to show confidence? These signals could indicate how the market’s trust in Compass evolves. For now, management will need to rebuild credibility and keep remaining shareholders onboard through transparency and execution. How effectively they do so is an open question that could influence the stock’s performance in coming months.

– Can losses be recovered (and how)? Ultimately, investors want to know if the recent losses are recoverable. This hinges on all of the above questions. If Compass can salvage tovecimig’s prospects (either via a creative regulatory strategy or additional data that convince stakeholders of its benefit), the stock could rebound significantly from the current lows. Alternatively, a strategic move such as a partnership with a larger oncology company or an outright sale of the company could unlock value and potentially mitigate losses. It’s also possible that positive surprises from other pipeline projects could gradually rebuild the market cap. On the other hand, if tovecimig is essentially a bust and no other catalyst emerges, CMPX might languish or even dwindle further. So the open question is: What is the recovery path, if any, for shareholders? Johnson Fistel’s message framing “recover your losses” hints at legal recourse, but real recovery would likely come from a scientific/clinical success or a corporate action that boosts the stock. Investors should stay tuned for news on FDA meetings, partnership announcements, and trial results as the potential drivers of any recovery.

In conclusion, Compass Therapeutics finds itself at a critical juncture. The company has cash on hand and a pipeline of innovative cancer drug candidates, but its lead program’s stumble has shaken confidence. The next few quarters will bring important answers – from regulators, from the lab, and perhaps from the courtroom. Whether those answers help CMPX claw back value or further compound investors’ pain remains to be seen. Given the uncertainties, investors should approach with caution, keeping a close eye on how management addresses the open questions and executes on its Plan B. The help that shareholders need may ultimately have to come from Compass itself – in the form of restored scientific credibility and business progress – with legal remedies only a last resort. For now, hope and skepticism coexist in the CMPX saga, and it will take concrete positive developments to truly recover the losses incurred.

Sources:

1. Compass Therapeutics 2025 Financial Results & Business Update – Compass IR/GlobeNewswire, Mar 5, 2026 (investors.compasstherapeutics.com) (investors.compasstherapeutics.com). 2. Johnson Fistel Investigates Compass Therapeutics – GlobeNewswire/Johnson Fistel PR, Apr 27, 2026 (www.globenewswire.com) (www.globenewswire.com). 3. Fierce Biotech – Compass’s Bispecific Misses OS Endpoint (James Waldron), Apr 27, 2026 (www.fiercebiotech.com) (www.fiercebiotech.com). 4. Chromareport – Trial Data Clouds OS, Stock Plummets ~60%, Apr 27, 2026 (hg04.chromareport.com) (hg04.chromareport.com). 5. RTT News – “Compass Therapeutics Plunges 63%”, Apr 27, 2026 (www.rttnews.com). 6. Investing.com News – William Blair on Compass Trial Results, Apr 27, 2026 (ng.investing.com) (ng.investing.com). 7. Compass Therapeutics SEC 10-K 2025 – Risk Factors & Financials (www.sec.gov) (www.sec.gov). 8. Compass Therapeutics SEC 10-K 2025 – Balance Sheet Data (www.sec.gov) (www.sec.gov). 9. Compass Therapeutics SEC 10-K 2025 – No Dividend Policy (www.sec.gov) (www.sec.gov). 10. Compass Therapeutics 8-K Filing (Trial Results) – Key Figures via StockTitan, Apr 27, 2026 (www.fiercebiotech.com) (www.stocktitan.net). 11. Compass Therapeutics Corporate Update – Compass IR, Jan 6, 2026 (investors.compasstherapeutics.com) (investors.compasstherapeutics.com). 12. Additional SEC filings and company reports for CMPX were referenced for financial and operational details (investors.compasstherapeutics.com) (www.sec.gov).

For informational purposes only; not investment advice.